OP  - building.jpg


<< Back

Samuel Riccitelli

Since June 2017, Mr. Riccitelli has been a member of the Board of Directors for Precipio, Inc., [NASDAQ: PRPO] and has served as Chairman of the Board for PRPO since November 2017. Mr. Riccitelli also served on the board of directors of Exagen Diagnostics, Inc. from October 2011 to September 2014. Previously, Mr. Riccitelli served as President and CEO and a director on the board of directors of Signal Genetics, Inc., a publicly traded molecular diagnostic company focused on serving the needs of patients suffering from Multiple Myeloma. For 10 years, Mr. Riccitelli served as the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic services company focused on the needs of community hematologists and oncologists. From 1995 to 2001, Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, including most recently as a vice president and general manager and as a board member for BD Ventures, LLC., a venture capital fund. From 1989 to 1994, he served in a number of positions at Puritan-Bennett Corporation, including most recently as general manager. Mr. Riccitelli received a B.A. in Biology from Washington and Jefferson College and a M.S. Eng. degree from The University of Texas in Mechanical & Biomedical Engineering.